GlaxoSmithKline (GSK), the world's second largest drugs group, has lost its action to prevent Swiss company Novartis making and selling cheap generic versions of Augmentin, GSK's leading antibiotic. GSK’s proceedings were aimed both against Novartis and its generic company, Geneva Pharmaceuticals. The US Court of Appeals for the Federal Circuit ruled in favour of Novartis and Geneva late on Friday, upholding Geneva's claim that seven of GSK's patents for the drug were "improper and should not have been used to extend patent protection for [GSK's] product".
Novartis and Geneva surprised the market in 2002 when it launched a generic version of Augmentin. The launch came after an unexpected US legal decision in May 2002 that a number of GSK's patents for Augmentin were invalid. GSK spent over a year fighting the decision but the original ruling has now been upheld, ending the legal dispute between the companies. In 2001 Augmentin had US sales of almost $1bn. In the first quarter of 2003, sales were $83m, down 64 per cent against the same period last year. A spokesman for GSK said the company remains committed to its newer Augmentin antibiotic medicines - Augmentin ES and XR - which now account for nearly 35 per cent of the total number of prescriptions for branded and generic Augmentin.
The IPKat commiserates with GSK’s shareholders on the likely diminution of the value of their share holdings in the light of this decision, but he reminds them that we live in a world of swings and roundabous - this decision should at least help to reduce their medical bills.
More on antibiotics here, here and here
Novartis and Geneva surprised the market in 2002 when it launched a generic version of Augmentin. The launch came after an unexpected US legal decision in May 2002 that a number of GSK's patents for Augmentin were invalid. GSK spent over a year fighting the decision but the original ruling has now been upheld, ending the legal dispute between the companies. In 2001 Augmentin had US sales of almost $1bn. In the first quarter of 2003, sales were $83m, down 64 per cent against the same period last year. A spokesman for GSK said the company remains committed to its newer Augmentin antibiotic medicines - Augmentin ES and XR - which now account for nearly 35 per cent of the total number of prescriptions for branded and generic Augmentin.
The IPKat commiserates with GSK’s shareholders on the likely diminution of the value of their share holdings in the light of this decision, but he reminds them that we live in a world of swings and roundabous - this decision should at least help to reduce their medical bills.
More on antibiotics here, here and here
GSK GETS THAT SICK FEELING AS ANTIBIOTIC PATENTS MEET AN EARLY DEATH
![GSK GETS THAT SICK FEELING AS ANTIBIOTIC PATENTS MEET AN EARLY DEATH]()
Reviewed by Jeremy
on
Sunday, November 23, 2003
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] Thou shalt not discriminate the Lego block over any other kind of product – GRUR speaks out on C-211/24](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgWJYQUJNvYydrZcjwSHPuxd14xX3_48aBusHKBogY-Wg1BPSJSABbFFjmGiUV3aqG2npP9xYaIl1vtWK5AsqGOQPgRD2TWFLhyyc4xGm1fHDD-tt9kHcrSSgAyju2P9wSKz0VW6h7D5MD4Hxd9vREyxKYzlMRNXxxtxc3DiNsXppfVaxgSxAMV/s72-c/21742619125_7c9e53cd39_o.png)
![[Guest post] Comparison of wine and gin: the EUIPO’s unquestionable Similarity Tool](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiNfTEBXiPVS0XjZi4mNE1OtXLxXiEp1PUgcUK7MMMXlfyTkO5SMXv-VCMXXNdS_F1XdMMxYca1VbBTGvvDeTVpo5x-5YwR7atQJmK3x32T8LACpf4308kht3nEtaxPwEPcGGrB0s5xjGktmQPOiVwPVLRO5JbW19qupc7xUtiVutvaWHow0OpBkA/s72-c/Picture%201.jpg)
![[Guest post] Muddying the waters of copyright – a rapid reaction to today’s IPEC decision which sees the sinking of the WaterRower’s claims for copyright protection](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh7chFANC7ppmZl4_nlR6_hZEcg6cOhVEJNVXqki4p82BoVlcLFotuOXzHWYD5lKLiiK_kRoWeXmJjjaV2DpoKsAWq8U3LFioO5W_841a9gcfDIFjvZWcGqfnr0jWJNtyXptIYR_8bxCssaDkJ9KMokuSqy1g65Il7p2hPwo4MfRCEGoUPQJesvbg/s72-w400-c-h189/Screenshot%202024-11-11%20at%2018.20.45.png)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html